Arequipa, Peru Clinical Trials

A listing of Arequipa, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Research Site
 (0.0 away) Contact site
  • 50 views
  • 02 Aug, 2021
  • +223 other locations
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

rituximab
cyclin d1
bendamustine
acalabrutinib
Research Site
 (0.0 away) Contact site
  • 1270 views
  • 24 Jul, 2021
  • +250 other locations
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

measurable disease
pembrolizumab
targeted therapy
metastasis
durvalumab
Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 0604)
 (0.9 away) Contact site
  • 51 views
  • 01 Aug, 2021
  • +187 other locations
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

paclitaxel
triple-negative breast cancer
formalin-fixed paraffin-embedded
cancer
measurable disease
Research Site
 (0.0 away) Contact site
  • 1387 views
  • 30 Jul, 2021
  • +309 other locations
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due …

squamous non-small cell lung cancer
cancer treatment
tyrosine
epidermal growth factor
EGFR
Research Site
 (0.0 away) Contact site
  • 811 views
  • 21 Jul, 2021
  • +171 other locations
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

advanced cancer
mk-3475
cancer
measurable disease
solid tumor
Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 3206)
 (0.9 away) Contact site
  • 16 views
  • 01 Aug, 2021
  • +148 other locations
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Ovarian Cancer or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy

Research Site
 (0.9 away) Contact site
  • 5 views
  • 01 Aug, 2021
  • +173 other locations
D9319C00001- 1L OC Mono Global RCT

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or endometroid ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who are in complete or …

bevacizumab
peritoneal cancer
interval debulking surgery
measurable disease
tumor debulking
Research Site
 (0.0 away) Contact site
  • 0 views
  • 22 Jul, 2021
  • +81 other locations
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.

paclitaxel
carboplatin
carboplatin/paclitaxel
lung carcinoma
gemcitabine
Research Site
 (0.0 away) Contact site
  • 251 views
  • 31 Jul, 2021
  • +318 other locations
A Phase 3 Efficacy Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

A study of zolbetuximab (IMAB362) plus mFOLFOX6 versus placebo plus mFOLFOX6 in subjects with Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical study for adult patients who have any of: advanced unresectable gastric …

Site PE51003
 (0.0 away) Contact site
  • 484 views
  • 23 Jul, 2021
  • +237 other locations